Download PDF
Thromb Haemost 1983; 50(04): 768-772
DOI: 10.1055/s-0038-1665308
Original Article
Schattauer GmbH Stuttgart

Effect of Neutral Proteases from Blood Leukocytes on Human Platelets

K Bykowska
1   The Department of Internal Diseases, Institute of Haematology, Warsaw, Poland
,
J Kaczanowska
2   The Department of Biochemistry, Institute of Rheumatology, Warsaw, Poland
,
M Karpowicz
1   The Department of Internal Diseases, Institute of Haematology, Warsaw, Poland
,
J Stachurska
2   The Department of Biochemistry, Institute of Rheumatology, Warsaw, Poland
,
J Kopeć
3   The Department of Radiobiology and Health Protection, Institute of Nuclear Research, Warsaw, Poland
› Author Affiliations
Further Information

Publication History

Received 25 April 1983

Accepted 27 July 1983

Publication Date:
18 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Two highly purified neutral proteases from human leukocytes i.e. elastase-like protease (ELP) and chymotrypsin-like protease (CLP) do not destroy human platelets since no difference was found in 51Cr liberation from control and enzyme-treated platelets. As with pancreatic chymotrypsin (α-CT) ELP does not induce the release of 3H-serotonin while CLP provokes 3H- serotonin secretion, in an enzyme concentration and time dependent fashion. The rate and degree of 3H-serotonin release by CLP is similar to that produced by thrombin. Incubation of platelets at 37° C for 30 min with α-CT or ELP renders them resistant to thrombin-releasing activity. Thrombin did not liberate any additional label from platelets which lost over 60% of serotonin during the preceding incubation with CLP. α-CT and ELP do not aggregate platelets either in the presence or absence of apyrase. CLP does aggregate platelets suspended in Tyrode buffer without apyrase but not in the presence of apyrase (100 mg/1). The action of α-CT, ELP and CLP on washed platelets induces a progressive prolongation of lag phase and a decrease in changes of light transmission during aggregation by thrombin. Similarly to α-CT-treated platelets, those subjected to CLP action aggregate in the presence of human fibrinogen.

It is concluded that: (1) neutral proteases possibly contribute to development of defects in platelet function in pathological states associated with liberation of leukocyte content into the circulation, (2) CLP similarly to a-CT, exposes fibrinogen receptors but in contrast to α-CT, CLP aggregates platelets and stimulates serotonin secretion.

Keywords

Neutral leukocytic proteases - Human blood platelets
 

  • References

  • 1 Rulot H. Intervention des leukocytes dans l’autolyse de la fibrine (Fibrinolyse de Dastre). Arch Int Physiol 1904; 1: 152
    PubMedGoogle Scholar
  • 2 Opie EL. Experimental pleurisy. Resolution of a fibrinous exudate J. Exp Med 1907; 9: 391
    CrossrefPubMedGoogle Scholar
  • 3 Haveman K, Janoff A. Neutral proteases of human polymorpho-nuclear leukocytes. Urban & Schwarzenberg; Baltimore - Munich: 1978
    Google Scholar
  • 4 Egbring R, Schmidt W, Fuchs G, Haveman K. Demonstration of granulocytic proteases in plasma of patients with acute leukemia and septicemia with coagulation defects. Blood 1977; 49: 219-231
    PubMedGoogle Scholar
  • 5 Kopeć M, Bykowska K, Lopaciuk S, Jeleńska M, Kaczanowska J, Sopata I, Wojtecka E. Effects of neutral proteases from human leukocytes on structure and biological properties of human factor VIII. Thromb Haemostas 1980; 43: 211-217
    PubMedGoogle Scholar
  • 6 Varadi K, Marossy K, Asboth G, Elödi P, Elödi S. Inactivation of human factor VIII by granulocyte proteases. Thromb Haemostas 1980; 43: 45-48
    PubMedGoogle Scholar
  • 7 Henriksson P, Nilsson IM, Ohlson K, Stenberg P. Granulocyte elastase activation and degradation of factor XIII. Thromb Res 1980; 18: 343-351
    CrossrefPubMedGoogle Scholar
  • 8 Kopeć M, Kaczanowska J, Stachurska J, Tomczak Z, Wojtecka-Lukasik E, Bykowska K, Lopaciuk S. Effects of granulocytic neutral proteases on some clotting factors. In: Progress in Fibrinolysis and Thrombolysis. Davidson JF, Nilsson IM, Astaed B. (eds) Churchill Livingston; Edinburgh, London, Melbourne, New York: 1981. 5 75-77
    Google Scholar
  • 9 Kopéc M, Wȩgrzynowicz Z, Ardelt W, Teisseyre E, Latallo ZS. Effect of elastolytic enzymes from human leukocyte granules and from pig pancreas on plasminogen fibrinogen and fibrin. In: Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Rowan RM, Samama MM, Desnoyers CP. (eds) Raven Press; New York: 1978. 3 417-425
    CrossrefGoogle Scholar
  • 10 Gramse M, Bingenheimer C, Schmidt W, Egbring R, Haveman K. Degradation products of fibrinogen by elastase-like neutral protease from human granulocytes. J Clin Invest 1978; 61: 1027-1033
    CrossrefPubMedGoogle Scholar
  • 11 McDonald JA, Kelley DG. Degradation of fibronectin by human leukocytic elastase. J Biol Chem 1980; 255: 8848-8858
    PubMedGoogle Scholar
  • 12 Vartio C. Characterization of the binding domains in the fragments cleaved by cathepsin G from human plasma fibronectin. Eur J Biochem 1982; 133: 223-233
    PubMedGoogle Scholar
  • 13 Brower MS, Harpel PC. Proteolytic cleavage and inactivation of α2-plasmin inhibitor and CT-inactivator by human polymorphonuclear elastase. J Biol Chem 1982; 257: 9849-9854
    CrossrefPubMedGoogle Scholar
  • 14 Klingeman HC, Egbring R, Holst F, Gramsa M, Haveman K. Digestion of α2-plasmin inhibitor by neutral proteases from human leukocytes. Thromb Res 1981; 24: 479-483
    CrossrefPubMedGoogle Scholar
  • 15 Hummel BC W. A modified spectrophotometric determination of chymotrypsin, trypsin and thrombin. Can J Biochem Physiol 1959; 37: 1393-1399
    CrossrefPubMedGoogle Scholar
  • 16 Visser L, Blout ER. The use of p-nitrophenyl N-tert-butylocarbonyl-L-alanine as a substrate for elastase. Biochim Biophys Acta 1972; 268: 257-260
    CrossrefPubMedGoogle Scholar
  • 17 Mustard JF, Perry DW, Ardlie NG, Packham MA. Preparation of suspensions of washed platelets from humans. Br J Haematol 1972; 22: 193-204
    CrossrefPubMedGoogle Scholar
  • 18 Nygaard K. A direct method of counting platelets in oxalated plasma. Proc Mayo Clin 1933; 8: 365
    PubMedGoogle Scholar
  • 19 Podolak-Dawidziak M, Konopka L, Pawelski S. Uwalnianie3H-hydroksytryptaminy z plytek pod wplywem surowicy chorych z maloplytkowosciami. Pol Arch Med Wew 1982; 68: 43
    PubMedGoogle Scholar
  • 20 Greenberg JP, Packham MA, Gucciona MA, Harfenist EJ, Orr JL, Kinlough-Rathbone RL, Perry DW, Mustard JF. The effect of pretreatment of human platelets with chymotrypsin on their responses to human fibrinogen and aggregation agents. Blood 1979; 54: 753-765
    PubMedGoogle Scholar
  • 21 Niewiarowski S, Budzyński AZ, Morinelli TA, Brudzynńki TM, Stewart GJ. Exposure of fibrinogen receptor on human platelets by proteolytic enzymes. J Biol Chem 1981; 256: 917-925
    PubMedGoogle Scholar
  • 22 Davey MG, Lüscher EF. Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets. Nature 1967; 216: 857-858
    CrossrefPubMedGoogle Scholar
  • 23 Martin BM, Reinman RD, Detwiler TC. Platelet stimulation by thrombin and other proteases. Biochemistry 1975; 14: 1308-1314
    CrossrefPubMedGoogle Scholar
  • 24 Podolsak B. Effect of thrombin, chymotrypsin and aggregated gamma-globulins on the proteins of the human platelet membrane. Thromb Haemostas 1977; 37: 396-406
    PubMedGoogle Scholar
  • 25 Okamura T, Jamieson GA. Platelet glycocalicin. Orientation of glycoproteins of the human platelet surface J Biol Chem 1976; 251: 5944-5949
    PubMedGoogle Scholar
  • 26 Starkey PM. Elastase and cathepsin G; the serine proteinases of human neutrophil leukocytes and spleen. In: Proteinases in mamma-lian cells and tissues. Barret AJ. (eds) North-Holland Publishing Company; Amsterdam, New York, Oxford: 1977: 57-89
    Google Scholar
  • 27 Plow EF. Leukocyte elastase release during blood coagulation. A potential mechanism for activation of the alternative fibrinolytic pathway J Clin Invest 1982; 69: 564-572
    CrossrefPubMedGoogle Scholar
  • 28 Cardamore JM, Edson JR, McArthur JR, Jacob HS. Abnormalities of platelet function in myeloproliferative disorders. JAMA 1972; 221: 270-273
    CrossrefPubMedGoogle Scholar
  • 29 Gerrard JM, Stoddard SR, Shapiro RS, Coccia PR, Ramsay NK C, Nesbit ME, Rao GH R, Krivit W, White JG. Platelet storage pool deficiency and prostaglandin synthesis in chronic granulocytic leukemia. Br J Haematol 1978; 40: 597-609
    CrossrefPubMedGoogle Scholar
  • 30 Castaldi PA, Bemdt MC, Booth W, Gregony C, Bull H, Greakes M. Evidence for a platelet membrane defect in the myeloproliferative disorders. Thromb Res 1982; 27: 601-609
    CrossrefPubMedGoogle Scholar
  • 31 Pareti FI, Gugliotta L, Mannucci L, Guardi A, Mannucci PM. Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders. Thromb Haemostas 1982; 47: 84-89
    PubMedGoogle Scholar
  • 32 Ireland H, Lane DA, Wolff S, Foadi M. In vivo platelet release in myèloproliferative disorders. Thromb Haemostas 1982; 48: 41-45
    PubMedGoogle Scholar
  • 33 Harper JH, Wohl H, Harper E. Platelet factor 4 an inhibitor of collagenase. Science 1978; 199: 991-992
    CrossrefPubMedGoogle Scholar
  • 34 Lonky AS A, Marsh J, Wohl H. Stimulation of human granulocyte elastase by platelet factor 4 and heparin. Biochem Biophys Res Commun 1978; 85: 1113-1118
    CrossrefPubMedGoogle Scholar